Emerging role of RNA m6A modifications in laryngeal squamous cell carcinoma: insights into tumorigenesis and therapeutic potential.

Laryngeal squamous cell carcinoma (LSCC) is one of the major malignant cancers worldwide. Emerging evidence has demonstrated that N6-methyladenosine (m6A) modification affects gene expression by regulating RNA metabolic processes, dynamically and reversibly regulated by its "writers", "erasers" and "readers". m6A modification plays an important role in the occurrence and development of various tumors. Recent studies have shown that m6A modifications are abnormally expressed in LSCC cells and tissues and participate in the malignant phenotypes of LSCC including cell proliferation, invasion, metastasis and chemotherapy resistance by mediating m6A regulators. This fundings may provide new directions for the molecular classification and targeted treatment of LSCC. In this review, we will focus on the molecular mechanism and potential clinical function of m6A modification in LSCC and emphasize its potential as a biomarker for the clinical diagnosis, prognosis, and treatment of LSCC.